Belite Bio Statistics
Total Valuation
Belite Bio has a market cap or net worth of $1.50 billion. The enterprise value is $1.41 billion.
| Market Cap | 1.50B |
| Enterprise Value | 1.41B |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Belite Bio has 29.79 million shares outstanding.
| Shares Outstanding | 29.79M |
| Owned by Insiders (%) | 59.01% |
| Owned by Institutions (%) | 0.44% |
| Float | 11.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 16.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.76, with a Debt / Equity ratio of 0.01.
| Current Ratio | 24.76 |
| Quick Ratio | 24.50 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,263.92 |
Financial Efficiency
Return on equity (ROE) is -48.00% and return on invested capital (ROIC) is -34.68%.
| Return on Equity (ROE) | -48.00% |
| Return on Assets (ROA) | -45.50% |
| Return on Capital (ROIC) | -34.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Belite Bio has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +214.56% in the last 52 weeks. The beta is -1.48, so Belite Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.48 |
| 52-Week Price Change | +214.56% |
| 50-Day Moving Average | 47.13 |
| 200-Day Moving Average | 42.61 |
| Relative Strength Index (RSI) | 63.93 |
| Average Volume (20 Days) | 68,802 |
Short Selling Information
| Short Interest | 222,484 |
| Short Previous Month | 36,076 |
| Short % of Shares Out | 1.88% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.67M |
| Pretax Income | -31.62M |
| Net Income | -31.63M |
| EBITDA | -31.20M |
| EBIT | -31.60M |
| Earnings Per Share (EPS) | -$1.19 |
Balance Sheet
The company has $88.16 million in cash and $886,000 in debt, giving a net cash position of $87.27 million or $2.93 per share.
| Cash & Cash Equivalents | 88.16M |
| Total Debt | 886,000 |
| Net Cash | 87.27M |
| Net Cash Per Share | $2.93 |
| Equity (Book Value) | 90.43M |
| Book Value Per Share | 3.04 |
| Working Capital | 86.31M |
Cash Flow
In the last 12 months, operating cash flow was -$29.84 million and capital expenditures -$63,000, giving a free cash flow of -$29.90 million.
| Operating Cash Flow | -29.84M |
| Capital Expenditures | -63,000 |
| Free Cash Flow | -29.90M |
| FCF Per Share | -$1.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Belite Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.12% |
| Shareholder Yield | -33.12% |
| Earnings Yield | -2.11% |
| FCF Yield | -1.99% |
Analyst Forecast
The average price target for Belite Bio is $50.25, which is -0.16% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.25 |
| Price Target Difference | -0.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |